Sugi Predict

Sugi Predict / Compounds / SCHEMBL1786589

SCHEMBL1786589

SCHEMBL1786589

COC(=O)C(N)CS(=O)(=O)O

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ CA14 Q9ULX7 3/20 0.39
▸ CA12 O43570 3/20 0.36
▸ CASR P41180 1/20 0.36
▸ KIF11 P52732 1/20 0.35
▸ SMN1; SMN2 Q16637 2/20 0.34
▸ CA9 Q16790 2/20 0.33
▸ PTPRB P23467 1/20 0.33
▸ CA7 P43166 1/20 0.33
▸ CA1 P00915 2/20 0.33
▸ CA2 P00918 2/20 0.33
▸ TP53 P04637 1/20 0.32
▸ SLC22A6 Q4U2R8 1/20 0.32
▸ KMT2A Q03164 2/20 0.32
▸ PMP22 Q01453 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.31
▸ MEN1 O00255 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3766175 1.00 CA14 (0.39) CA14CA12CASRKIF11SMN1; SMN2
SCHEMBL1786590 1.00 CA14 (0.39) CA14CA12CASRKIF11SMN1; SMN2
Hydrochloric Acid SCHEMBL17393224 0.98 CA14 (0.38) CA14CA12CASRKIF11SMN1; SMN2
Hydrochloric Acid SCHEMBL17393225 0.98 CA14 (0.38) CA14CA12CASRKIF11SMN1; SMN2
SCHEMBL16007484 0.83 CA14 (0.39) CA14CA12CASRKIF11SMN1; SMN2
SCHEMBL7940365 0.83 CA14 (0.39) CA14CA12CASRKIF11SMN1; SMN2
SCHEMBL951149 0.81 TP53 (0.39) CA12CA9CA1CA2TP53
SCHEMBL20528274 0.81 TP53 (0.39) CA12CA9CA1CA2TP53
SCHEMBL20528290 0.81 PMP22 (0.38) CA14CA12CASRKIF11CA1
SCHEMBL22648515 0.80 SMN1; SMN2 (0.36) CA14CA12CASRKIF11SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110218168-A A kind of preparation method of the sodium salt of N- (alltrans-view Huang acyl group)-L- cysteic acid methyl ester 上海现代药物制剂工程研究中心有限公司 2019-09-10 — — CN claimed
CN-100360502-C Retinol derivatives, their use in the treatment of cancer and for potentiating the efficacy of other cytotoxic agents ARDENIA INVESTMENTS LTD (GB) 2008-01-09 — — CN claimed
EP-1765363-A2 NEW COMPOSITIONS GLUCOGENE MEDICAL HFM AB (SE) 2007-03-28 — — EP claimed
WO-2006006933-A2 ANTIPROLIFERATIVE COMPOSITIONS COMPRISING ARYL SUBSTITUTED XYLOPYRANOSIDE DERIVATIVES GLUCOGENE MEDICAL HFM AB (SE) 2006-01-19 — — WO claimed
CN-1668583-A Retinol derivatives, their use in the treatment of cancer and for enhancing the efficacy of other cytotoxic agents ARDENIA INVESTMENTS LTD (GB) 2005-09-14 — — CN claimed
US-20250051375-A1 ANTI-HIV COMPOUNDS GILEAD SCIENCES, INC. 2025-02-13 — — US disclosed
EP-3386947-B1 METHOD FOR PRODUCING N-RETINOYLAMINOALKANE SULFONIC ACID OASMIA PHARMACEUTICAL AB (SE) 2021-05-19 — — EP disclosed
US-20210015802-A1 METHOD FOR MANUFACTURING NOVEL NITROGEN-CONTAINING COMPOUND OR SALT THEREOF AND MANUFACTURING INTERMEDIATE OF NOVEL NITROGEN-CONTAINING COMPOUND OR SALT THEREOF FUJIFILM CORPORATION (JP) 2021-01-21 — — US disclosed
CN-110218168-A A kind of preparation method of the sodium salt of N- (alltrans-view Huang acyl group)-L- cysteic acid methyl ester 上海现代药物制剂工程研究中心有限公司 2019-09-10 — — CN disclosed
CN-110218168-A A kind of preparation method of the sodium salt of N- (alltrans-view Huang acyl group)-L- cysteic acid methyl ester 上海现代药物制剂工程研究中心有限公司 2019-09-10 — — CN disclosed
CN-110218168-A A kind of preparation method of the sodium salt of N- (alltrans-view Huang acyl group)-L- cysteic acid methyl ester 上海现代药物制剂工程研究中心有限公司 2019-09-10 — — CN disclosed
EP-3239142-B1 CONDENSED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2019-07-03 — — EP disclosed
US-7033520-B2 Metal chelating compositions for protein purification, detection or binding SIGMA-ALDRICH CO. (US) 2006-04-25 — — US disclosed
EP-1627683-A2 Metal chelating compositions Sigma Aldrich Company (US) 2006-02-22 — — EP disclosed
CN-1668583-A Retinol derivatives, their use in the treatment of cancer and for enhancing the efficacy of other cytotoxic agents ARDENIA INVESTMENTS LTD (GB) 2005-09-14 — — CN disclosed
EP-1276716-B1 METAL CHELATING COMPOSITIONS SIGMA ALDRICH CO (US) 2005-06-22 — — EP disclosed
US-20040092031-A1 Metal chelating compositions for protein purification, detection or binding SIGMA - ALDRICH CO. 2004-05-13 — — US disclosed
US-6623655-B1 Nitrilotriacetic acid derivatives; improved specificity and stability; protein purification, detection and/or binding SIGMA-ALDRICH CO. 2003-09-23 — — US disclosed
EP-1276716-A2 METAL CHELATING COMPOSITIONS Sigma-Aldrich Company (US) 2003-01-22 — — EP disclosed
WO-2001081365-A2 METAL CHELATING COMPOSITIONS SIGMA-ALDRICH CO. (US) 2001-11-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210015802-A1 METHOD FOR MANUFACTURING NOVEL NITROGEN-CONTAINING COMPOUND OR SALT THEREOF AND MANUFACTURING INTERMEDIATE OF NOVEL NITROGEN-CONTAINING COMPOUND OR SALT THEREOF C5, C9, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 CA14 941/4885CA12 688/4885CASR 2682/4885
US-20250051375-A1 ANTI-HIV COMPOUNDS CCR5, CD4, NFATC1 CA14 4190/4885CA12 4488/4885CASR 4486/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.